Humanized mouse models for Epstein Barr virus infection

被引:45
作者
Muenz, Christian [1 ]
机构
[1] Univ Zurich, Inst Expt Immunol, Viral Immunobiol, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
NATURAL-KILLER-CELLS; B-CELLS; T-CELLS; MICE; EBV; EXPRESSION; DIFFERENTIATION; REPLICATION; ACTIVATION; RESPONSES;
D O I
10.1016/j.coviro.2017.07.026
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
It is essential for the human immune system to control Epstein Barr virus (EBV), because this common human gamma-herpesvirus efficiently spreads through the human population with more than 90% being persistently infected after 20 years of age even in developed countries. Moreover, it threatens each host with its potent growth transforming properties, readily immortalizing human B cells into persistently growing lymphoma cell lines. Since this virus only infects humans, mice with reconstituted human immune system components provide an informative in vivo model to study EBV infection, the associated tumor formation and immune control thereof. They recapitulate the different infection programs in human B cells, allow modeling EBV driven lymphoma formation and interrogation of the key cytotoxic lymphocyte responses that are also required to control this pathogen in humans. The respective lessons that were taught by these investigations will be discussed in this review as well as the challenges in the future to address the whole portfolio of EBV associated diseases and how they could be prevented by EBV specific immunotherapies.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 50 条
  • [21] An Epstein-Barr Virus (EBV) Mutant with Enhanced BZLF1 Expression Causes Lymphomas with Abortive Lytic EBV Infection in a Humanized Mouse Model
    Ma, Shi-Dong
    Yu, Xianming
    Mertz, Janet E.
    Gumperz, Jenny E.
    Reinheim, Erik
    Zhou, Ying
    Tang, Weihua
    Burlingham, William J.
    Gulley, Margaret L.
    Kenney, Shannon C.
    JOURNAL OF VIROLOGY, 2012, 86 (15) : 7976 - 7987
  • [22] In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures
    Ni, Chao
    Chen, Yuhui
    Zeng, Musheng
    Pei, Rongjuan
    Du, Yong
    Tang, Linquan
    Wang, Mengyi
    Hu, Yazhuo
    Zhu, Hanyu
    He, Meifang
    Wei, Xiawei
    Wang, Shan
    Ning, Xiangkai
    Wang, Manna
    Wang, Jufang
    Ma, Li
    Chen, Xinwen
    Sun, Qiang
    Tang, Hong
    Wang, Ying
    Wang, Xiaoning
    CELL RESEARCH, 2015, 25 (07) : 785 - 800
  • [23] Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection
    Pender, Michael P.
    AUTOIMMUNITY REVIEWS, 2009, 8 (07) : 563 - 568
  • [24] Chronic Active Epstein-Barr Virus Infection: Is It Immunodeficiency, Malignancy, or Both?
    Fujiwara, Shigeyoshi
    Nakamura, Hiroyuki
    CANCERS, 2020, 12 (11) : 1 - 15
  • [25] NK Cell Influence on the Outcome of Primary Epstein-Barr Virus Infection
    Chijioke, Obinna
    Landtwing, Vanessa
    Muenz, Christian
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [26] Epstein-Barr virus infection mechanisms
    Chesnokova, Liudmila S.
    Hutt-Fletcher, Lindsey M.
    CHINESE JOURNAL OF CANCER, 2014, 33 (11) : 545 - 548
  • [27] Dysregulated Epstein-Barr virus infection in patients with CIDP
    Luenemann, J. D.
    Tackenberg, B.
    Stein, A.
    Wandinger, K. P.
    Oertel, W. H.
    Wagner, H. J.
    Muenz, C.
    Meisel, H.
    Sommer, N.
    Zipp, F.
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 218 (1-2) : 107 - 111
  • [28] Genetics of Epstein-Barr virus infection
    Hiraki, A
    Fujii, N
    Masuda, K
    Ikeda, K
    Tanimoto, M
    BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (07) : 369 - 372
  • [29] Epstein-Barr Virus Infection as an Epigenetic Driver of Tumorigenesis
    Kaneda, Atsushi
    Matsusaka, Keisuke
    Aburatani, Hiroyuki
    Fukayama, Masashi
    CANCER RESEARCH, 2012, 72 (14) : 3445 - 3450
  • [30] Primary Epstein-Barr virus infection
    Dunmire, Samantha K.
    Verghese, Priya S.
    Balfour, Henry H., Jr.
    JOURNAL OF CLINICAL VIROLOGY, 2018, 102 : 84 - 92